Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patientsMarket Watch • 12/13/22
Why Merck's $250 Million Investment In Moderna May Have Just Paid OffInvestors Business Daily • 12/13/22
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 TrialAccesswire • 12/13/22
Merck Global Health Innovation Fund and P74 Ventures Make Strategic Investment in TransVoyant for Intelligent, ‘Self Aware' Supply Chain PlatformBusiness Wire • 12/13/22
MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An EdgeSeeking Alpha • 12/11/22
Early Q4 Earnings Results and Analyst Reports for Merck, Bristol-Myers & DeereZacks Investment Research • 12/09/22
Is Merck Stock A Buy After Surging To A Fresh High On Its Imago Buyout Plans?Investors Business Daily • 12/06/22
Merck & Co., Inc. (MRK) 2022 5th Annual Evercore ISI HealthCONx Conference (Transcript)Seeking Alpha • 12/01/22
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual MeetingBusiness Wire • 12/01/22